• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

头孢比普与对照抗生素对当代欧洲分离株（2016 - 19年）的活性。

activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016-19).

作者信息

Canton Rafael, Hamed Kamal, Wiktorowicz Tatiana, Redder Nowel, Jemmely Noelle, Quevedo Juan, Santerre Henriksen Anne

机构信息

Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.

出版信息

JAC Antimicrob Resist. 2022 Mar 24;4(2):dlac030. doi: 10.1093/jacamr/dlac030. eCollection 2022 Apr.

DOI:10.1093/jacamr/dlac030
PMID:35350131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8947215/
Abstract

OBJECTIVES

To evaluate the susceptibility to ceftobiprole of clinical bacterial isolates obtained from hospitalized patients in Europe.

METHODS

A total of 20 000 non-duplicate bacterial isolates were collected in 2016-19 from patients with documented infections at medical centres located in 17 countries in Europe. Bacterial identification was confirmed and susceptibility to ceftobiprole and comparator agents was tested using the EUCAST broth microdilution methodology and interpretive criteria by a central microbiology laboratory.

RESULTS

Of the 20 000 isolates, 10 007 (50.0%) were Gram-positive and 9993 (50.0%) were Gram-negative. The most common species was (35.0%), followed by (15.0%), (11.1%), (11.0%), (9.7%) and (3.0%). Overall, 99.7% (6981/7000) of , including 99.5% (3483/3502) of MRSA, 97.8% (2941/3007) of , 100% (605/605) of and 76.3% (5492/7197) of Enterobacterales isolates were susceptible to ceftobiprole. Susceptibility to ceftobiprole was higher for isolates from northern and western Europe as compared with eastern and southern Europe.

CONCLUSIONS

Ceftobiprole continues to exhibit potent and broad-spectrum activity against Gram-positive and Gram-negative clinical isolates from Europe, and as expected, with a slight north-to-south and west-to-east susceptibility gradient.

摘要

目的

评估从欧洲住院患者中分离出的临床细菌菌株对头孢托罗的敏感性。

方法

2016年至2019年期间，从欧洲17个国家的医疗中心有感染记录的患者中收集了总共20000株非重复细菌菌株。细菌鉴定由中央微生物实验室确认，并使用EUCAST肉汤微量稀释方法和解释标准检测对头孢托罗及对照药物的敏感性。

结果

在这20000株菌株中，10007株（50.0%）为革兰氏阳性菌，9993株（50.0%）为革兰氏阴性菌。最常见的菌种是[具体菌种1]（35.0%），其次是[具体菌种2]（15.0%）、[具体菌种3]（11.1%）、[具体菌种4]（11.0%）、[具体菌种5]（9.7%）和[具体菌种6]（3.0%）。总体而言，99.7%（6981/7000）的[相关菌种1]，包括99.5%（3483/3502）的耐甲氧西林金黄色葡萄球菌、97.8%（

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e5/8947215/4805be4b44de/dlac030f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e5/8947215/4805be4b44de/dlac030f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33e5/8947215/4805be4b44de/dlac030f1.jpg

相似文献

1
activity of ceftobiprole and comparator antibiotics against contemporary European isolates (2016-19).头孢比普与对照抗生素对当代欧洲分离株（2016 - 19年）的活性。
JAC Antimicrob Resist. 2022 Mar 24;4(2):dlac030. doi: 10.1093/jacamr/dlac030. eCollection 2022 Apr.
2
Susceptibility of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2019 from different European territories.2019 年来自不同欧洲地区的革兰氏阳性和革兰氏阴性临床分离株对头孢托罗的敏感性。
J Glob Antimicrob Resist. 2022 Jun;29:393-397. doi: 10.1016/j.jgar.2022.05.001. Epub 2022 May 10.
3
In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.抗耐甲氧西林金黄色葡萄球菌头孢菌素头孢比普对近期源自欧洲的革兰氏阳性和革兰氏阴性分离株的体外活性谱
J Antimicrob Chemother. 2008 Mar;61(3):595-602. doi: 10.1093/jac/dkm492. Epub 2008 Jan 23.
4
Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories.对来自不同欧洲地区 2018 年的革兰阳性和革兰阴性临床分离株的头孢托罗的监测。
J Glob Antimicrob Resist. 2021 Sep;26:326-329. doi: 10.1016/j.jgar.2021.07.012. Epub 2021 Jul 27.
5
Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.头孢比普对2005年至2010年在欧洲、土耳其和以色列分离出的60000多种临床细菌病原体的活性。
Antimicrob Agents Chemother. 2014 Jul;58(7):3882-8. doi: 10.1128/AAC.02465-14. Epub 2014 Apr 28.
6
Antimicrobial activity of ceftobiprole and comparator agents when tested against gram-positive and -negative organisms collected across China (2016-2018).头孢托罗匹酯和比较剂药物在中国（2016-2018 年）收集的革兰氏阳性和阴性菌的抗菌活性。
BMC Microbiol. 2022 Nov 26;22(1):282. doi: 10.1186/s12866-022-02699-4.
7
Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).头孢托罗培南（一种新型抗耐甲氧西林金黄色葡萄球菌头孢菌素）对当代病原体的抗菌活性：哨兵抗菌监测计划（2005 - 2006年）的结果
Diagn Microbiol Infect Dis. 2008 May;61(1):86-95. doi: 10.1016/j.diagmicrobio.2008.02.008. Epub 2008 Apr 2.
8
Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study.来自欧洲和中东地区的革兰氏阳性和革兰氏阴性分离株的头孢托罗比对活性：CLASS 研究。
J Antimicrob Chemother. 2011 Jan;66(1):151-9. doi: 10.1093/jac/dkq397.
9
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).头孢比普与对照药物在针对2015年从欧洲收集的当代革兰氏阳性和阴性菌进行测试时的抗菌活性。
Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.
10
In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.2009 年加拿大医院分离的革兰阳性和革兰阴性病原菌的体外 ceftaroline 活性。
Antimicrob Agents Chemother. 2011 Jun;55(6):2837-46. doi: 10.1128/AAC.01787-10. Epub 2011 Mar 14.

引用本文的文献

1
Ceftobiprole activity against multidrug-resistant clinical isolates collected in the United States from 2016 through 2022.头孢比普对2016年至2022年在美国收集的多重耐药临床分离株的活性。
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0140224. doi: 10.1128/aac.01402-24. Epub 2025 Jan 13.
2
Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.临床分离株中黏菌素耐药性的流行情况：一项系统评价和荟萃分析。
Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024.
3
Antibiotic Resistance to Molecules Commonly Prescribed for the Treatment of Antibiotic-Resistant Gram-Positive Pathogens: What Is Relevant for the Clinician?

本文引用的文献

1
Surveillance of ceftobiprole against Gram-positive and Gram-negative clinical isolates from 2018 from different European territories.对来自不同欧洲地区 2018 年的革兰阳性和革兰阴性临床分离株的头孢托罗的监测。
J Glob Antimicrob Resist. 2021 Sep;26:326-329. doi: 10.1016/j.jgar.2021.07.012. Epub 2021 Jul 27.
2
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).头孢托罗匹酯与万古霉素加氨曲南治疗急性细菌性皮肤和皮肤结构感染的比较：一项 3 期、随机、双盲试验（TARGET）的结果。
Clin Infect Dis. 2021 Oct 5;73(7):e1507-e1517. doi: 10.1093/cid/ciaa974.
3
对常用于治疗耐抗生素革兰氏阳性病原体的分子的抗生素耐药性：临床医生应关注什么？
Pathogens. 2024 Jan 19;13(1):88. doi: 10.3390/pathogens13010088.
4
Safety and Efficacy of a Single Procedure of Extraction and Reimplantation of Infected Cardiovascular Implantable Electronic Device (CIED) in Comparison with Deferral Timing: An Observational Retrospective Multicentric Study.与延期时机相比，感染性心血管植入式电子设备（CIED）单次取出与重新植入手术的安全性和有效性：一项观察性回顾性多中心研究。
Antibiotics (Basel). 2023 Jun 2;12(6):1001. doi: 10.3390/antibiotics12061001.
Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data.
英国和爱尔兰的 BSAC 监测数据显示：头孢洛林对比头孢托罗匹酯对葡萄球菌和肺炎链球菌的活性。
J Antimicrob Chemother. 2020 Nov 1;75(11):3239-3243. doi: 10.1093/jac/dkaa306.
4
In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates.对 880 株耐甲氧西林金黄色葡萄球菌的欧洲呼吸道感染分离株进行头孢洛林体外药敏试验，然后对头孢洛林耐药分离株进行全基因组测序。
Diagn Microbiol Infect Dis. 2020 Apr;96(4):114978. doi: 10.1016/j.diagmicrobio.2019.114978. Epub 2019 Dec 27.
5
Ceftobiprole versus daptomycin in bacteremia: a novel protocol for a double-blind, Phase III trial.头孢洛林对比达托霉素治疗菌血症：一项双盲、III 期试验的新方案。
Future Microbiol. 2020 Jan;15(1):35-48. doi: 10.2217/fmb-2019-0332. Epub 2020 Jan 10.
6
Staphylococcus aureus from hospital-acquired pneumonia from an Italian nationwide survey: activity of ceftobiprole and other anti-staphylococcal agents, and molecular epidemiology of methicillin-resistant isolates.意大利全国性调查中的医院获得性肺炎金黄色葡萄球菌：头孢洛林和其他抗葡萄球菌药物的活性，以及耐甲氧西林金黄色葡萄球菌分离株的分子流行病学。
J Antimicrob Chemother. 2019 Dec 1;74(12):3453-3461. doi: 10.1093/jac/dkz371.
7
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis.2015 年欧盟及欧洲经济区因抗生素耐药菌感染导致的死亡人数和伤残调整生命年：基于人群的模型分析。
Lancet Infect Dis. 2019 Jan;19(1):56-66. doi: 10.1016/S1473-3099(18)30605-4. Epub 2018 Nov 5.
8
High Rate of Ceftobiprole Resistance among Clinical Methicillin-Resistant Isolates from a Hospital in Central Italy.意大利中部某医院耐甲氧西林金黄色葡萄球菌临床分离株中头孢妥仑耐药率较高。
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.01663-18. Print 2018 Dec.
9
Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015).头孢比普与对照药物在针对2015年从欧洲收集的当代革兰氏阳性和阴性菌进行测试时的抗菌活性。
Diagn Microbiol Infect Dis. 2018 May;91(1):77-84. doi: 10.1016/j.diagmicrobio.2017.12.020. Epub 2018 Jan 3.
10
Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.头孢比普对2005年至2010年在欧洲、土耳其和以色列分离出的60000多种临床细菌病原体的活性。
Antimicrob Agents Chemother. 2014 Jul;58(7):3882-8. doi: 10.1128/AAC.02465-14. Epub 2014 Apr 28.